Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

BACKGROUND: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma. METHODS: Patients had ECOG performance status 0–2 and normal organ function. Dacarbazine was administered on day 1 and da...

Full description

Saved in:

Bibliographic Details
Main Authors:	Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2012
Subjects:	Clinical Study
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3251861/ https://ncbi.nlm.nih.gov/pubmed/22127285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.514
Tags:	Add Tag No Tags, Be the first to tag this record!

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

Similar Items